Literature DB >> 35546371

Assessment of bone health in patients with prostate cancer using cancer staging computed tomography.

Mototaka Sato1, Masafumi Kashii2, Atsuki Matsukawa1, Ryoya Mizuno1, Mai Akiyama1, Takashi Kamatani3, Satoshi Kamido4, Norichika Ueda1, Jiro Nakayama5, Norihide Tei1, Hideki Yoshikawa3, Osamu Miyake1.   

Abstract

PURPOSE: To evaluate the utility of vertebral Hounsfield unit (HU) values from computed tomography (CT) in cancer staging as a supplementary screening tool for bone health among prostate cancer (PCa) patients.
METHODS: T-scores of bone mineral density (BMD) in each lumbar vertebra (L1-L4) and hip for newly diagnosed PCa patients (N = 139) were measured using dual-energy X-ray absorptiometry (DXA). The degenerative changes in each lumbar vertebra were assessed, and the HU values of trabecular bone in axial CT images of each vertebral body (vertebral CT-HU value) were measured using staging CT.
RESULTS: 556 vertebrae were analyzed. 326 of 556 (59%) lumbar vertebrae had degenerative changes. The vertebral CT-HU value was positively correlated with the lumbar BMD T-score, with higher correlation coefficients observed in vertebrae without degenerative changes (r = 0.655, N = 230) when compared to vertebrae with degenerative changes (r = 0.575, N = 326). The thresholds matching BMD T-scores of - 2.0 and - 1.5 set by cancer treatment-induced bone loss guidelines were 95 HU and 105 HU, respectively. Based on the intervention threshold (lumbar BMD T-score <  - 1.5), 15.1% of PCa patients required osteoporosis treatment; and, this value increased to 30.9% when L1-L4 CT-HU thresholds that corresponded to BMD T-score <  - 1.5 were used.
CONCLUSION: Lumbar BMD values from DXA may not reflect true bone health in PCa patients who often have lumbar degenerative diseases. Thresholds based on the vertebral CT-HU value can be used as a supplementary method to identify PCa patients who need anti-osteoporosis drugs.
© 2022. The Japanese Society Bone and Mineral Research.

Entities:  

Keywords:  Bone mineral density; CT Hounsfield unit value; Dual-energy X-ray absorptiometry; Lumbar degenerative disease; Prostate cancer

Mesh:

Year:  2022        PMID: 35546371     DOI: 10.1007/s00774-022-01328-4

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.976


  27 in total

1.  Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.

Authors:  Seiichi Kato; Makoto Kawase; Daiki Kato; Takashi Ishida; Masahiro Uno; Yoshinori Fujimoto; Takako Masue; Naruyasu Masue; Takashi Deguchi
Journal:  J Bone Miner Metab       Date:  2018-01-08       Impact factor: 2.626

2.  Official Positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Position Development Conference.

Authors:  Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman
Journal:  J Clin Densitom       Date:  2008 Jan-Mar       Impact factor: 2.617

3.  Management manual for cancer treatment-induced bone loss (CTIBL): position statement of the JSBMR.

Authors:  Seiji Fukumoto; Satoshi Soen; Tetsuya Taguchi; Takashi Ishikawa; Hisashi Matsushima; Masakazu Terauchi; Shigeo Horie; Toshiyuki Yoneda; Toshitsugu Sugimoto; Toshio Matsumoto
Journal:  J Bone Miner Metab       Date:  2020-02-04       Impact factor: 2.626

4.  Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study.

Authors:  B Hager; K Kraywinkel; B Keck; A Katalinic; M Meyer; S R Zeissig; R Scheufele; M P Wirth; J Huber
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-09-13       Impact factor: 5.554

Review 5.  Temporal trends and racial disparities in global prostate cancer prevalence.

Authors:  Timothy R Rebbeck; Gabriel P Haas
Journal:  Can J Urol       Date:  2014-10       Impact factor: 1.344

6.  Risk of fracture after androgen deprivation for prostate cancer.

Authors:  Vahakn B Shahinian; Yong-Fang Kuo; Jean L Freeman; James S Goodwin
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

7.  Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications.

Authors:  Perry J Pickhardt; B Dustin Pooler; Travis Lauder; Alejandro Muñoz del Rio; Richard J Bruce; Neil Binkley
Journal:  Ann Intern Med       Date:  2013-04-16       Impact factor: 25.391

8.  Fracture risk in Danish men with prostate cancer: a nationwide register study.

Authors:  Bo Abrahamsen; Morten F Nielsen; Peter Eskildsen; Jens Thorup Andersen; Steen Walter; Kim Brixen
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

Review 9.  Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Authors:  Peyman Hadji; Matti S Aapro; Jean-Jacques Body; Michael Gnant; Maria Luisa Brandi; Jean Yves Reginster; M Carola Zillikens; Claus-C Glüer; Tobie de Villiers; Rod Baber; G David Roodman; Cyrus Cooper; Bente Langdahl; Santiago Palacios; John Kanis; Nasser Al-Daghri; Xavier Nogues; Erik Fink Eriksen; Andreas Kurth; Rene Rizzoli; Robert E Coleman
Journal:  J Bone Oncol       Date:  2017-03-23       Impact factor: 4.072

Review 10.  The prevention of fragility fractures in patients with non-metastatic prostate cancer: a position statement by the international osteoporosis foundation.

Authors:  Luisella Cianferotti; Francesco Bertoldo; Marco Carini; John A Kanis; Alberto Lapini; Nicola Longo; Giuseppe Martorana; Vincenzo Mirone; Jean-Yves Reginster; Rene Rizzoli; Maria Luisa Brandi
Journal:  Oncotarget       Date:  2017-05-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.